Axsome Therapeutics Inc
AXSM
Market Cap$5.13B
Close$
$19.95
80.8% downside
Current Fair Value
80.8% downsideOvervalued by 80.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.13 Billion |
|---|---|
| Enterprise Value | $5.03 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-5.99 |
| Beta | 0.47 |
| Outstanding Shares | 48,871,163 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -18.28 |
|---|---|
| PEG | 139.73 |
| Price to Sales | 13.01 |
| Price to Book Ratio | 104.1 |
| Enterprise Value to Revenue | 11.65 |
| Enterprise Value to EBIT | -18.44 |
| Enterprise Value to Net Income | -19 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 3.94 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Axsome Therapeutics Inc
CEO: Herriot Tabuteau Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory tre...